Shenzhen Kangtai Biological Products (SHE:300601) launched the phase III clinical trials of the adsorbed acellular pertussis, diphtheria, and tetanus (component) combined vaccine, according to a Shenzhen bourse filing on May 30.
The vaccine is intended to prevent pertussis, diphtheria, and tetanus in infants and young children aged 2 months and older.